Interactive Effects of Anti-Cardiovascular Disease Drugs and Anti-Osteoporosis Drugs on Two Diseases

Jiaying Xu; Xiaoli Hou; Yifei Liu; Lei Xing; Lijun Zhao; Xue Wang; Jingjing Liu; Haoqi Zou; Faming Tian

doi:10.54097/03rj2463

Authors

Jiaying Xu
Xiaoli Hou
Yifei Liu
Lei Xing
Lijun Zhao
Xue Wang
Jingjing Liu
Haoqi Zou
Faming Tian

DOI:

https://doi.org/10.54097/03rj2463

Keywords:

Osteoporosis, Cardiovascular Disease, Beta-blockers, Statins, Renin-angiotensin System Inhibitors, Calcium Antagonists, Nitrates, Thiazide Diuretics, Vitamin D

Abstract

Cardiovascular disease (CVD) and osteoporosis are common diseases in the middle-aged and elderly population, and the number of people affected by these two diseases has been steadily increasing against the background of a deepening global ageing population. The relationship between cardiovascular diseases and osteoporosis is complex, especially whether the related therapeutic drugs affect the development of the other disease while acting on one disease has become a hot research topic in the medical field. The purpose of this paper is to summarise the intrinsic connection between cardiovascular diseases and osteoporosis by systematically combing the authoritative literature at home and abroad in recent years, and to comprehensively analyse the mechanism of action of anti-cardiovascular disease and osteoporosis drugs, and to explore the influence of the therapeutic drugs for one disease on the other disease. This will provide strong support for clinicians to formulate more scientific and reasonable comprehensive treatment plans, and thus promote the progress and development of cardiovascular disease, osteoporosis and their co-morbidities management.

Downloads

Download data is not yet available.

References

[1] Li Y, Hao W, Guan J, et al. Relationship between indices of circulating blood cells and bone homeostasis in osteoporosis[J]. Frontiers in Endocrinology, 2022, 13: 965290.

[2] Ghosh M, Majumdar S R. Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis[J]. Endocrine, 2014, 46(3): 397-405.

[3] Deligiorgi M V, Panayiotidis M I, Siasos G, et al. Osteoporosis Entwined with Cardiovascular Disease: the Implication of Osteoprotegerin and the Example of Statins[J]. Current Medicinal Chemistry, 2021, 28(7): 1443-1467.

[4] Azeez T A. Osteoporosis and cardiovascular disease: a review[J]. Molecular Biology Reports, 2023, 50(2): 1753-1763.

[5] ZHAO Lianyou, SUN Ningling, SUN Yingxian, et al. Chinese expert consensus on the use of α/β-blockers in the treatment of hypertension[J]. Chinese Journal of Hypertension, 2016, 24(6): 521-526.

[6] Sabidó M, Hohenberger T, Grassi G. Pharmacological intervention in hypertension using beta-blockers: real-world evidence for long-term effectiveness[J]. Pharmacological Research, 2018, 130: 191-197.

[7] Gao YY, Gao Q, Xu Shanshan, et al. Clinical application of β-blockers for precise intervention of sympathetic excitability in hypertensive patients[J]. Chinese Journal of Hypertension, 2019, 27(11): 1065-1069.

[8] Guan Z, Liu Y, Luo L, et al. Sympathetic innervation induces exosomal miR-125 transfer from osteoarthritic chondrocytes, disrupting subchondral bone homeostasis and aggravating cartilage damage in aging mice[J]. Journal of Advanced Research, 2024: S2090-1232(24)00122-X.

[9] Khosla S. Evidence in humans for bone as an endocrine organ regulating energy metabolism[J]. Current Opinion in Endocrine and Metabolic Research, 2023, 31: 100471.

[10] Hijazi N, Alourfi Z. Association between Hypertension, Antihypertensive Drugs, and Osteoporosis in Postmenopausal Syrian Women: A Cross-Sectional Study[J]. Advances in Medicine, 2020, 2020: 7014212.

[11] Nevola K T, Kiel D P, Zullo A R, et al. miRNA Mechanisms Underlying the Association of Beta Blocker Use and Bone Mineral Density[J]. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 2021, 36(1): 110-122.

[12] Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system[J]. Cell, 2002, 111(3): 305-317.

[13] Choi H J, Park C, Lee Y K, et al. Risk of fractures in subjects with antihypertensive medications: a nationwide claim study[J]. International Journal of Cardiology, 2015, 184: 62-67.

[14] Rauch U, Osende J I, Chesebro J H, et al. Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins[J]. Atherosclerosis, 2000, 153(1): 181-189.

[15] Ruscica M, Ferri N, Santos R D, et al. Lipid Lowering Drugs: Present Status and Future Developments[J]. Current Atherosclerosis Reports, 2021, 23(5): 17.

[16] Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins[J]. Science (New York, N.Y.), 1999, 286(5446): 1946-1949.

[17] Xiong M, Xue Y, Zhu W, et al. Comparative efficacy and safety of statins for osteoporosis: a study protocol for a systematic review and network meta- analysis[J]. BMJ Open, 2022, 12(5): e054158.

[18] An T, Hao J, Sun S, et al. Efficacy of statins for osteoporosis: a systematic review and meta-analysis[J]. Osteoporosis International, 2017, 28(1): 47-57.

[19] Leutner M, Matzhold C, Bellach L, et al. Diagnosis of osteoporosis in statin-treated patients is dose-dependent[J]. Annals of the Rheumatic Diseases, 2019, 78(12): 1706-1711.

[20] Jwa C S, Yi H J, Oh S J, et al. Prior Use of 3-Hydroxy-3-Methyl-Glutaryl-Coenzyme A Reductase Inhibitor, Simvastatin Fails to Improve Outcome after Experimental Intracerebral Hemorrhage[J]. Journal of Korean Neurosurgical Society, 2011, 50(5): 403-408.

[21] SU Huixia, LI Haiming, CUI Xinjie, et al. Effects of statin therapy on bone metabolism: a meta-analysis[J]. Chinese Journal of Osteoporosis, 2020, 26(11): 1632-1639.

[22] Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database[J]. BMJ (Clinical research ed.), 2010, 340: c2197.

[23] Yongtao Z, Kunzheng W, Jingjing Z, et al. Glucocorticoids activate the local renin-angiotensin system in bone: possible mechanism for glucocorticoid- induced osteoporosis[J]. Endocrine, 2014, 47(2): 598-608.

[24] XIAO Hao, CHEN Liao Bin, ZHANG Xian Rong, et al. Progress in the study of renin-angiotensin systemogenesis and therapeutic targets in osteoporosis[J]. Chinese Journal of Pharmacology and Toxicology, 2016, 30(10): 1114-1119.

[25] García-Testal A, Monzó A, Rabanaque G, et al. [Evolution of the bone mass of hypertense menopausal women in treatment with fosinopril][J]. Medicina Clinica, 2006, 127(18): 692-694.

[26] Zhang Yan, Deng Hongwen. Progress of renin-angiotensin system in bone biological activity[J]. Chinese Journal of Osteoporosis, 2010, 16(1): 64-66.

[27] Ağaçayak K S, Güven S, Koparal M, et al. Long-term effects of antihypertensive medications on bone mineral density in men older than 55 years[J]. Clinical Interventions in Aging, 2014, 9: 509-513.

[28] Chang C M, Chen Y C, Wu W T, et al. Association between clinical use of nifedipine and the risk of osteoporosis: a nationwide retrospective cohort study[J]. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the United States[J]. Osteoporosis Foundation of the USA, 2023, 34(7): 1223-1230.

[29] Ushijima K, Liu Y, Maekawa T, et al. Protective effect of amlodipine against osteoporosis in stroke-prone spontaneously hypertensive rats[J]. European Journal of Pharmacology, 2010, 635(1-3): 227-230.

[30] Menger M M, Merscher B, Scheuer C, et al. Amlodipine accelerates bone healing in a stable closed femoral fracture model in mice[J]. European Cells & Materials, 2021, 41: 592-602.

[31] Bai Xuexi. Evaluation and analysis of the efficacy and rationality of combined oral and intravenous application of nitrates[J]. Journal of Jilin Medical College, 2017, 38(1): 15-18.

[32] Rejnmark L, Vestergaard P, Mosekilde L. Decreased fracture risk in users of organic nitrates: a nationwide case-control study[J]. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 2006, 21(11): 1811-1817.

[33] Jamal S A, Cummings S R, Hawker G A. Isosorbide Mononitrate Increases Bone Formation and Decreases Bone Resorption in Postmenopausal Women: a Randomized Trial* [J]. Journal of Bone and Mineral Research, 2004, 19(9): 1512-1517.

[34] Wimalawansa S J. Nitric oxide and bone[J]. Annals of the New York Academy of Sciences, 2010, 1192: 391-403.

[35] ZHOU Xiaohong, ZHONG Shilong. Recent advances in pharmacogenomics of drugs commonly used in cardiovascular diseases[J]. Advances in Pharmacy, 2018, 42(4): 269-283.

[36] Wang J, Su K, Sang W, et al. Thiazide Diuretics and the Incidence of Osteoporotic Fracture: A Systematic Review and Meta-Analysis of Cohort Studies[J]. Frontiers in Pharmacology, 2019, 10: 1364.

[37] Li Juqin. Progress on the correlation between different types of antihypertensive drugs and osteoporosis[J]. Chinese Journal of Osteoporosis, 2023, 29(8): 1231-1233+1244.

[38] Van der Burgh A C, Oliai Araghi S, Zillikens M C, et al. The impact of thiazide diuretics on bone mineral density and the trabecular bone score: the Rotterdam Study[J]. Bone, 2020, 138: 115475.

[39] Xiao X, Xu Y, Wu Q. Thiazide diuretic usage and risk of fracture: a meta-analysis of cohort studies[J]. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2018, 29(7): 1515-1524.

[40] Dvorak M M, De Joussineau C, Carter D H, et al. Thiazide diuretics directly induce osteoblast differentiation and mineralised nodule formation by interacting with a sodium chloride co-transporter in bone[J]. Journal of the American Society of Nephrology: JASN, 2007, 18(9): 2509-2516.

[41] Bokrantz T, Schiöler L, Boström K B, et al. Antihypertensive drug classes and the risk of hip fracture: results from the Swedish primary care cardiovascular database[J]. Journal of Hypertension, 2020, 38(1): 167-175.

[42] Jiang W, Wu D B, Xiao G B, et al. An epidemiological survey of vitamin D deficiency and its influencing factors[J]. Medicina Clinica, 2020, 154(1): 7-12.

[43] Reid I R, Bolland M J. Calcium and/or Vitamin D Supplementation for the Prevention of Fragility Fractures: Who Needs It?[J]. Nutrients, 2020, 12(4): 1011.

[44] Guidelines for the diagnosis and treatment of primary osteoporosis (2022)[J]. Chinese Journal of Osteoporosis and Bone Mineral Salt Diseases, 2022, 15(6): 573-611.

[45] YANG Shanru, WANG Xiaoming. Progress of vitamin D in the prevention and treatment of common diseases in the elderly[J]. International Journal of Geriatrics, 2024, 45(4): 385-389.

[46] Thompson B, Waterhouse M, English D R, et al. Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial[J]. BMJ (Clinical research ed.), 2023, 381: e075230.

[47] Pilz S, Verheyen N, Grübler M R, et al. Vitamin D and cardiovascular disease prevention[J]. Nature Reviews Cardiology, 2016, 13(7): 404-417.

[48] Fuggle N R, Cooper C, Harvey N C, et al. Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs[J]. Drugs, 2020, 80(15): 1537-1552.

[49] ZHANG Jianping, LU Liqing, CHEN Yongchang, et al. Re-evaluation of the systematic evaluation of bisphosphonate treatment for primary osteoporosis causing serious adverse reactions[J]. Pharmacy Today, 2018, 28(2): 134-139.

[50] Almeida M, Iyer S, Martin-Millan M, et al. Estrogen receptor-α signalling in osteoblast progenitors stimulates cortical bone accrual[J]. The Journal of Clinical Investigation, 2013, 123(1): 394-404.

[51] Cheng C H, Chen L R, Chen K H. Osteoporosis Due to Hormone Imbalance: an Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover[J]. International Journal of Molecular Sciences, 2022, 23(3): 1376.

[52] Zhu L, Shi J, Luu T N, et al. Hepatocyte estrogen receptor alpha mediates estrogen action to promote reverse cholesterol transport during Western-type diet feeding[J]. Molecular Metabolism, 2018, 8: 106-116.

[53] WU Shaoze, WANG Lihong, GU Jian. Research progress on the effects of estrogen and its receptors on lipid metabolism[J]. Journal of Difficult Diseases, 2017, 16(4): 419-422+428.

[54] Väänänen H K, Härkönen P L. Estrogen and bone metabolism [J]. Maturitas, 1996, 23 Suppl: S65-69.

[55] Chinese Medical Association, Journal of the Chinese Medical Association, Chinese Medical Association Branch of Family Medicine, et al. Primary osteoporosis primary care guidelines (2019) [J]. Chinese Journal of Family Medicine, 2020, 19(4): 304-315.

[56] Fox J. Developments in parathyroid hormone and related peptides as bone-formation agents[J]. Current Opinion in Pharmacology, 2002, 2(3): 338-344.

[57] Wang Y H, Liu Y, Rowe D W. Effects of transient PTH on early proliferation, apoptosis, and subsequent differentiation of osteoblast in primary osteoblast cultures[J]. American Journal of Physiology. Endocrinology and Metabolism, 2007, 292(2): E594-603.

[58] Keleşoğlu Ş, Yilmaz Y, Gökay F, et al. Atrial electromechanical delay is impaired in patients with primary hyperparathyroidism[J]. Endokrynologia Polska, 2021, 72(5): 550-557.

[59] Yu L, Tomlinson J E, Alexander S T, et al. Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism [J]. Calcified Tissue International, 2017, 101 (6): 641-653.

[60] Srinivasan A, Wong F K, Karponis D. Calcitonin: A useful old friend[J]. Journal of Musculoskeletal & Neuronal Interactions, 2020, 20(4): 600-609.

[61] McLaughlin M B, Awosika A O, Jialal I. Calcitonin [M]// StatPearls. Treasure Island (FL): StatPearls Publishing, 2024.

[62] Chesnut C H, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis. The prevent recurrence of osteoporotic fractures study. PROOF Study Group[J]. The American Journal of Medicine, 2000, 109(4): 267-276.

[63] Moreira L M, Takawale A, Hulsurkar M, et al. Paracrine signalling by cardiac calcitonin controls atrial fibrogenesis and arrhythmia [J]. Nature, 2020, 587(7834): 460-465.

[64] CuiLing Chen. Exploring the adverse reactions and countermeasures of salmon calcitonin injection in clinical practice[J]. Straits Pharmacology, 2021, 33(4): 215-216.

[65] HUANG Xiaowei, BAO Zhaohai, HU Chengui. Effect of zoledronic acid combined with egcalcitonin on postoperative bone mineral density and fracture healing in osteoporotic fracture patients[J]. Clinical Rational Use of Drugs, 2024, 17(21): 111-113+120.

[66] Ayers C, Kansagara D, Lazur B, et al. Effectiveness and Safety of Treatments to Prevent Fractures in People with Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians[J]. Annals of Internal Medicine, 2023, 176(2): 182-195.

[67] Händel M N, Cardoso I, Von Bülow C, et al. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials[J]. BMJ (Clinical research ed.), 2023, 381: e068033.

[68] Tsai W H, Sung F C, Muo C H, et al. Antiosteoporosis medications and cardiovascular disease: a population-based nationwide nested case-control study[J]. Frontiers in Pharmacology, 2023, 14: 1220174.

[69] Miller P D, Adachi J D, Albergaria B H, et al. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease[J]. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 2022, 37(8): 1437-1445.

[70] Lim S Y. Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk[J]. Women's Health (London, England), 2022, 18: 17455057221125577.

[71] Kawaguchi H. Serious Adverse Events With Romosozumab Use in Japanese Patients: Need for Clear Formulation of Contraindications Worldwide[J]. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 2020, 35(5): 994-995.